XORTX Therapeutics Inc. highlights recent research linking genetic factors to gout and high uric acid levels, supporting their approach to treating these conditions by inhibiting xanthine oxidase. The company’s findings in rodent models suggest XO over-expression is a key target in treating gout and polycystic kidney disease. The company plans to use oxypurinol in a clinical trial for gout therapy. XORTX also announces board changes and clarifies details of a recent financing round. Additionally, the company provides an update on the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited.

Read more at GlobeNewswire: XORTX Announces Pioneering Research on Genome-Wide